賽昂生醫 CEO 獲得台灣環球生技最佳CEO獎

Date: January 10, 2024
Dr. Kuo-Hsiang Chuang Recognized for Pioneering Cancer Therapy
For more details, visit Global Bio & Investment.

CytoArm’s CEO, Dr. Kuo-Hsiang Chuang, has been named Taiwan’s top young biomedical leader by Global Bio & Investment Magazine. This accolade highlights his groundbreaking work in developing the Armed-T cell technology, a non-viral gene modification method that offers a safer and more effective cancer treatment alternative. Dr. Chuang’s dedication and innovation are paving the way for new advancements in cancer therapy, bringing hope to patients worldwide.

Technology Overview

• Professor Kuang-Hsiang Chuang and his team at CytoArms Biotechnology developed the Armed-T technology.
• Unlike traditional CAR-T therapy, Armed-T does not require viral gene modification.
• T-cells are directly equipped with personalized anti-cancer armor.
• These Armed-T cells effectively recognize and attack tumors.

Clinical Trials and Potential Impact

• The product CTA-02, based on Armed-T technology, is entering phase I clinical trials.
• It has the potential to challenge the current leading CAR-T immunotherapy.
• Professor Chuang emphasizes the life-saving potential of this technology for cancer patients.